Patient Response

RUCONEST® in children with HAE has shown a comparable safety and efficacy profile to adults1,2*

RUCONEST® is indicated for treatment of acute HAE attacks in children ≥2 years with HAE due to C1-INH deficiency2**

95.9% (70/73, N=20) of attacks in children aged 5-14 years were treated with a single dose of RUCONEST®1

Median time to onset of symptom relief was 60 minutes1

Incidence of AEs in patients treated for >1 attack did not increase1

*RUCONEST® has an established safety profile in children with HAE >5 years of age.
**RUCONEST® is licensed for children 2 years and above with limited data available for children aged between 2-5 years.²
AE: adverse event; HAE: hereditary angioedema;

RUCONEST® remains effective regardless of BMI3

  • Patients with a high BMI (≥30 kg/m2) tend to experience a higher frequency of attacks3
  • For patients with a BMI ≥30 kg/m2, some acute HAE treatments may be less effective4
  • RUCONEST® remains effective in patients weighing ≥180 kg3

Emergency setting use

Why is RUCONEST® well suited for use in the emergency setting?

Fast, effective, sustained relief in one dose regardless of attack location or severity5-7

A RUCONEST® vial has a shelf life of 4 years, at room temperature, making it convenient for storing at the hospital2

Established safety profile for adults and children ≥5 years1,2

C1 esterase inhibitor (C1-INH) returned to normal levels* in 94% of patients, regardless of age or weight, with just one dose**3

*The normal range of plasma C1-INH in healthy individuals is between 0.70–1.30 U/mL.⁸
**Dosing of RUCONEST® is weight dependent and one dose is, therefore, based on patient weight as follows; <84 kg: 50 U/kg (1–2 vials); ≥84 kg: fixed dose of 2 vials (4200 U).²

Understanding the early signs of an acute HAE attack

Findings from research conducted with patients and healthcare professionals in the UK and Spain in 2021/20228,9

The patient perspective

208 patients with HAE in the UK and Spain participated in a survey. Patients self-reported answers based on their perceptions and beliefs. The survey excluded patients below 16 years of age.8

Early signs of an acute HAE attack can often be identified by patients

Pressure or tightness in skin8

Feeling tired
or fatigued8

Pressure or widespread
abdominal pain8

Mood changes8

Overall, 60% could identify early signs of an acute HAE attack (n=208).8

The HCP perspective

8 HCPs across Europe (Bulgaria, Spain, Italy, Hungary, UK, France, and Netherlands) and Israel were interviewed on HAE and the early signs of an acute HAE attack.9

HCP insights into the early signs of an acute HAE attack

Early signs and attacks are believed by most healthcare professionals to be a single event9

Early signs do not always result in acute HAE attacks9

Erythema marginatum (EM) is considered a reliable early sign of acute HAE attacks9

Early signs of acute HAE attacks can be difficult to differentiate from other illnesses9

The importance of treating early

According to the international WAO/EAACI guideline for the management of HAE published in 2022, early treatment is associated with a shorter time to resolution of symptoms and a shorter total attack duration regardless of attack severity. Therefore, it is recommended that HAE attacks should be treated as early as possible.10

Encouraging an open conversation

Differentiating early signs

Patients can be supported in differentiating early signs from other ‘everyday’ aches and pains. The most frequently reported sites of early signs are:8

Abdominal pain

Swelling in hands or feet



Tightness of skin, genitals (for males)

Explaining ‘treating early’

Healthcare professionals could discuss early signs of an acute HAE attack with patients to help take appropriate action.

Understanding your patient’s individual treatment requirements can help initiate conversations around managing the early signs of an acute HAE attack.11

RUCONEST®: fast, effective, sustained relief, in one dose4-8


Identical amino acid sequence to native human C1-INH9


Rapid onset of action6,7


96% of patients experience relief with just one dose5,8


One dose stops attacks for at least 3 days in 93% of patients4

RUCONEST® is indicated for treatment of acute angioedema attacks in adults, adolescents, and children (aged 2 years and above) with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.


  1. Reshef A, et al. Pediatr Allergy Immunol. 2019;30(5):562-568.
  2. RUCONEST® SmPC. July 2023.
  3. Farrell C, et al. Br J Clin Pharmacol. 2013;76(6):897-907.
  4. Bernstein JA, et al. Clinical Therapeutics. 2014;36(4):518-525.
  5. Li H, et al. J Allergy Clin Immunol Pract. 2015;3(3):417-423.
  6. Riedl M, et al. Ann Allergy Asthma Immunol. 2013;110(4):295-299.
  7. Riedl M, et al. Ann Allergy Asthma Immunol. 2014;112(2):163-169.
  8. Van Veen H, et al. J Biotechnol 2012;162(2-3):319-326.
  9. Riedl M. Clin Drug Investig 2015;35(7):407-417.